XERS

MKT CAP:$1B

Xeris Biopharma Holdings, Inc.

Market Cap

$1B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$5.99-$1.36 (-18.50%)

Apr 24, 2026

Company Details

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glu...

CEO

John Shannon

IPO Date

Jun 21, 2018

Website

www.xerispharma.com

Key Metrics TTM

Revenue

$292M

+43.7% YoY

Net Income

$554.0K

EPS (Diluted)

-$0.01

Free Cash Flow

$38M

Revenue / Share

$1.62

Gross Margin

81.7%

Operating Margin

8.5%

Net Margin

0.2%

FCF Margin

12.9%

P/S

3.6x

P/E

1886.1x

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Mar 2, 2026

$292M+43.7%EPS $0.00

Q4 2025

Mar 2, 2026

$86M+42.8%EPS $0.06

Q3 2025

Nov 6, 2025

$74M+37.1%EPS $0.00

Q2 2025

Aug 7, 2025

$72M+48.8%EPS -$0.01

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$22M	$16M	-$29M
Q2 22	$25M	$20M	-$19M
Q3 22	$30M	$24M	-$19M
Q4 22	$33M	$27M	-$15M
Q1 23	$33M	$28M	-$13M
Q2 23	$38M	$30M	-$16M
Q3 23	$48M	$40M	-$5M
Q4 23	$44M	$34M	-$10M
Q1 24	$41M	$35M	-$14M
Q2 24	$48M	$38M	-$8M
Q3 24	$54M	$41M	-$13M
Q4 24	$60M	$51M	$2M
Q1 25	$60M	$51M	-$3M
Q2 25	$72M	$57M	$4M
Q3 25	$74M	$63M	$7M
Q4 25	$86M	$67M	$17M

Valuation

Quarter	P/S	P/E
Q1 22	16.4x	—
Q2 22	13.0x	—
Q3 22	10.6x	—
Q4 22	9.5x	—
Q1 23	8.6x	—
Q2 23	7.8x	—
Q3 23	6.8x	—
Q4 23	6.4x	—
Q1 24	6.1x	—
Q2 24	5.8x	—
Q3 24	5.6x	—
Q4 24	5.1x	—
Q1 25	4.7x	—
Q2 25	4.2x	—
Q3 25	3.9x	—
Q4 25	3.6x	1886.1x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$48M	-$48M
Q2 22	-$21M	-$21M
Q3 22	-$18M	-$18M
Q4 22	-$16M	-$16M
Q1 23	-$26M	-$26M
Q2 23	-$14M	-$15M
Q3 23	-$15M	-$15M
Q4 23	$6M	$6M
Q1 24	-$20M	-$20M
Q2 24	-$10M	-$11M
Q3 24	-$8M	-$8M
Q4 24	$2M	$2M
Q1 25	-$10M	-$10M
Q2 25	$182.0K	$10M
Q3 25	$18M	$18M
Q4 25	$20M	$20M

Capital Expenditures

Quarter	CapEx
Q1 22	$16.0K
Q2 22	$216.0K
Q3 22	$176.0K
Q4 22	$132.0K
Q1 23	$238.0K
Q2 23	$2M
Q3 23	$345.0K
Q4 23	$132.0K
Q1 24	$164.0K
Q2 24	$397.0K
Q3 24	$87.0K
Q4 24	$220.0K
Q1 25	$13.0K
Q2 25	$13.0K
Q3 25	$363.0K
Q4 25	$333.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+169.3%	+105.1%
Q2 22	+184.1%	+27.5%
Q3 22	+169.4%	+37.0%
Q4 22	+53.0%	-30.9%
Q1 23	+50.4%	-9.1%
Q2 23	+50.2%	+22.1%
Q3 23	+62.6%	+9.7%
Q4 23	+33.9%	+12.2%
Q1 24	+22.4%	+18.1%
Q2 24	+26.5%	+4.2%
Q3 24	+12.3%	+26.2%
Q4 24	+35.4%	+7.7%
Q1 25	+47.9%	+15.2%
Q2 25	+48.8%	+19.2%
Q3 25	+37.1%	+0.7%
Q4 25	+42.8%	+18.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$3M	15.0%
Q2 22	$3M	12.5%
Q3 22	$3M	9.9%
Q4 22	$3M	8.3%
Q1 23	$3M	7.7%
Q2 23	$3M	7.7%
Q3 23	$2M	5.1%
Q4 23	$3M	6.2%
Q1 24	$4M	9.3%
Q2 24	$4M	8.8%
Q3 24	$7M	12.5%
Q4 24	$4M	6.0%
Q1 25	$4M	7.4%
Q2 25	$5M	7.0%
Q3 25	$8M	10.3%
Q4 25	$5M	6.1%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 22	$6M	$36M
Q2 22	$4M	$33M
Q3 22	$6M	$34M
Q4 22	$5M	$34M
Q1 23	$5M	$34M
Q2 23	$6M	$38M
Q3 23	$5M	$37M
Q4 23	$6M	$38M
Q1 24	$8M	$38M
Q2 24	$6M	$40M
Q3 24	$6M	$45M
Q4 24	$6M	$40M
Q1 25	$8M	$44M
Q2 25	$8M	$44M
Q3 25	$7M	$46M
Q4 25	$8M	$48M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$104M	$28M	$132M
Q2 22	$95M	$16M	$112M
Q3 22	$84M	$9M	$93M
Q4 22	$122M	$0	$122M
Q1 23	$51M	$44M	$95M
Q2 23	$46M	$34M	$81M
Q3 23	$46M	$20M	$66M
Q4 23	$67M	$5M	$72M
Q1 24	$63M	$25M	$87M
Q2 24	$58M	$20M	$78M
Q3 24	$59M	$10M	$69M
Q4 24	$72M	$0	$72M
Q1 25	$58M	$0	$58M
Q2 25	$59M	$0	$59M
Q3 25	$92M	$0	$92M
Q4 25	$111M	$0	$111M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	135M	+10.7%	+120.5%
Q2 22	136M	+0.4%	+104.2%
Q3 22	136M	+0.3%	+104.4%
Q4 22	136M	+0.0%	+11.5%
Q1 23	137M	+0.9%	+1.6%
Q2 23	137M	+0.1%	+1.3%
Q3 23	138M	+0.5%	+1.6%
Q4 23	138M	+0.0%	+1.6%
Q1 24	141M	+1.7%	+2.5%
Q2 24	148M	+5.6%	+8.0%
Q3 24	149M	+0.4%	+7.9%
Q4 24	149M	+0.1%	+7.9%
Q1 25	152M	+2.2%	+8.5%
Q2 25	156M	+2.3%	+5.1%
Q3 25	178M	+13.9%	+19.2%
Q4 25	180M	+1.4%	+20.8%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$75.1K	294
Q2 22	$86.1K	294
Q3 22	$101.1K	294
Q4 22	$93.4K	355
Q1 23	$93.5K	355
Q2 23	$107.1K	355
Q3 23	$136.1K	355
Q4 23	$117.7K	377
Q1 24	$107.8K	377
Q2 24	$127.5K	377
Q3 24	$143.9K	377
Q4 24	$152.5K	394
Q1 25	$152.6K	394
Q2 25	$181.6K	394
Q3 25	$188.8K	394
Q4 25	$197.3K	435

Revenue / Employee